Rexgenero treats first patients in CLI trial
London, UK-based Rexgenero has reached a major milestone in treating the first patient in a late-stage trial with its lead product, cell therapy REX-001.
Read More
Tag: critical limb ischaemia
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
- CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
- FDA approves new high dose Spinraza regimen for SMA
